QT Interval Prolongation and Risk Assessment of Antiarrhythmic Drugs

QT interval prolongation is a well-known electrophysiological phenomenon that can predispose individuals to life-threatening arrhythmias, particularly torsades de pointes, and sudden cardiac death. The use of antiarrhythmic drugs (AADs) can further exacerbate the risk of QT prolongation, making it essential to assess this risk when prescribing and managing these therapies. This review explores the mechanisms underlying QT interval prolongation, focusing on the role of potassium and sodium ion channels in cardiac repolarization. It provides a comprehensive evaluation of the various classes of AADs, including class I (sodium channel blockers), class III (potassium channel blockers), and newer agents, discussing their effects on the QT interval and the risk of arrhythmias. The review also highlights the factors that influence the degree of QT prolongation, such as genetic predisposition, electrolyte imbalances, drug interactions, and the presence of structural heart disease. We discuss risk stratification strategies, including the use of electrocardiograms (ECGs) for monitoring QT intervals, and the role of clinical guidelines in identifying patients at high risk. Additionally, the article addresses pharmacogenomic considerations, where genetic variations in drug-metabolizing enzymes or ion channels may influence individual susceptibility to QT prolongation. Finally, we explore therapeutic strategies to mitigate the risks of QT prolongation, including adjusting drug doses, switching to safer antiarrhythmic agents, and correcting underlying risk factors like electrolyte disturbances. The ultimate goal is to optimize antiarrhythmic therapy while minimizing the risk of life-threatening arrhythmias in vulnerable patients.